ConductScience.org, home

Paper9108427

Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation.

Slattery JT and 27 others. Blood, 1997. Cited by 277 papers, by iCite.

Cite this record

ConductScience Library. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Papers, record 9108427. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/9108427

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation.
PubMed
Journal
Blood
PubMed
Year
1997
PubMed
Publication types
Journal Article, Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
277
iCite
Relative citation ratio, by iCite
7.96
iCite
Revised in PubMed
2021-02-16
PubMed

Authors28

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Slattery JTJ T
2Clift RAR A
3Buckner CDC D
4Radich JJ
5Storer BB
6Bensinger WIW I
7Soll EE
8Anasetti CC
9Bowden RR
10Bryant EE
11Chauncey TT
12Deeg HJH J
13Doney KCK C
14Flowers MM
15Gooley TT
16Hansen JAJ A
17Martin PJP J
18McDonald GBG B
19Nash RR
20Petersdorf EWE W

Source PubMed

See all 28 authorsDownload CSV of authors

Topics22

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Bone Marrow TransplantationMajor topic
BusulfanMajor topic
Leukemia, Myeloid, Accelerated PhaseMajor topic
Leukemia, Myeloid, Chronic-PhaseMajor topic
Transplantation ConditioningMajor topic
Adult
Cause of Death
Cyclophosphamide
Female
Graft Rejection
Graft vs Host Disease
Humans
Infections
Male
Middle Aged
Neoplasm, Residual
Quality of Life
Recurrence
Remission Induction
Survival Analysis
Transplantation, Homologous
Treatment Outcome

Source PubMed

Download CSV of topics

Grants4

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
CA 15704NCI NIH HHSUnited StatesP01CA015704PubMed and NIHNIH RePORTER
CA 18029NCI NIH HHSUnited StatesP01CA018029PubMed and NIHNIH RePORTER
CA 18221NCI NIH HHSUnited StatesP01CA018221PubMed and NIHNIH RePORTER
P30CA015704NIHNIH RePORTER

Download CSV of grants

Cited by106

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 277 citations.

PMIDTitleJournalYearIn PapersSource
42517921Development of a simplified population pharmacokinetic-pharmacodynamic framework for exposure-informed risk stratification of neutropenia during amrubicin treatment.Cancer Chemother Pharmacol2026https://conductscience.org/library/papers/42517921PubMed
40788512Targeted drug monitoring in oncology for personalized treatment with use of next generation analytics.Discov Oncol2025https://conductscience.org/library/papers/40788512PubMed
37491812
Saliva as a noninvasive sampling matrix for therapeutic drug monitoring of intravenous busulfan in Chinese patients undergoing hematopoietic stem cell transplantation: A prospective population pharmacokinetic and simulation study.
CPT Pharmacometrics Syst Pharmacol2023https://conductscience.org/library/papers/37491812PubMed
37379285Association between busulfan exposure and survival in patients undergoing a CD34+ selected stem cell transplantation.Blood Adv2023https://conductscience.org/library/papers/37379285PubMed
36820303Characterization and quantitation of busulfan DNA adducts in the blood of patients receiving busulfan therapy.Mol Ther Oncolytics2023https://conductscience.org/library/papers/36820303PubMed
36710948Evaluating the Efficacy, Toxicity and Pharmacokinetic Profile of Oral Busulfan in Allogeneic Stem Cell Transplant Patients.Blood Cell Ther2022https://conductscience.org/library/papers/36710948PubMed
35336021Development of a Population Pharmacokinetic Model of Busulfan in Children and Evaluation of Different Sampling Schedules for Precision Dosing.Pharmaceutics2022https://conductscience.org/library/papers/35336021PubMed
34523110Pharmacokinetically guided, once-daily intravenous busulfan in combination with fludarabine for elderly AML/MDS patients as a conditioning regimen for allogeneic stem cell transplantation.Int J Hematol2021https://conductscience.org/library/papers/34523110PubMed
33231122Comparison of fixed dose reduced-intensity conditioning with fludarabine and busulfan to PK-guided busulfan AUC (FluBu4K) in hematopoietic stem cell transplant for AML/MDS.Leuk Lymphoma2021https://conductscience.org/library/papers/33231122PubMed
32886279Pharmacokinetics of intravenous busulfan as condition for hematopoietic stem cell transplantation: comparison between combinations with cyclophosphamide and fludarabine.Int J Hematol2021https://conductscience.org/library/papers/32886279PubMed
31851762Population pharmacokinetic modelling of busulfan and the influence of body composition in paediatric Fanconi anaemia patients.Br J Clin Pharmacol2020https://conductscience.org/library/papers/31851762PubMed
31555969Analysis of glutathione S-transferase and cytochrome P450 gene polymorphism in recipients of dose-adjusted busulfan-cyclophosphamide conditioning.Int J Hematol2020https://conductscience.org/library/papers/31555969PubMed
31467455Bayesian non-parametric survival regression for optimizing precision dosing of intravenous busulfan in allogeneic stem cell transplantation.J R Stat Soc Ser C Appl Stat2019https://conductscience.org/library/papers/31467455PubMed
31326610Busulfan Pharmacokinetics and Precision Dosing: Are Patients with Fanconi Anemia Different?Biol Blood Marrow Transplant2019https://conductscience.org/library/papers/31326610PubMed
31212080
A Phase II Multicenter Study of the Addition of Azacitidine to Reduced-Intensity Conditioning Allogeneic Transplant for High-Risk Myelodysplasia (and Older Patients with Acute Myeloid Leukemia): Results of CALGB 100801 (Alliance).
Biol Blood Marrow Transplant2019https://conductscience.org/library/papers/31212080PubMed
31160806Use of busulfan in conditioning for allogeneic hematopoietic stem cell transplantation in adults: a survey by the Transplant Complications Working Party of the EBMT.Bone Marrow Transplant2019https://conductscience.org/library/papers/31160806PubMed
31136799Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement.Biol Blood Marrow Transplant2019https://conductscience.org/library/papers/31136799PubMed
31089278
Pharmacokinetics analysis results are similar for oral compared to intravenous busulfan in patients undergoing hematopoietic stem cell transplantation, except for the earlier onset of mucositis. A controlled clinical study.
Bone Marrow Transplant2019https://conductscience.org/library/papers/31089278PubMed
30532055Reduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDS.Bone Marrow Transplant2019https://conductscience.org/library/papers/30532055PubMed
29884851Pharmacokinetic and clinical outcomes when ideal body weight is used to dose busulfan in obese hematopoietic stem cell transplant recipients.Bone Marrow Transplant2019https://conductscience.org/library/papers/29884851PubMed

See all 106 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/9108427

GET https://conductscience.org/api/papers/v1/9108427/authors?page=2